Publication:
Intermittent administration of the circulating form of human parathyroid hormone (hPTH-1-37) prevents bone loss in ovariectornized rats

Simple item page
dc.bibliographiccitation.firstpage13
dc.bibliographiccitation.issue1
dc.bibliographiccitation.journalEuropean Journal Of Medical Research
dc.bibliographiccitation.lastpage20
dc.bibliographiccitation.volume12
dc.contributor.authorStephan, S.
dc.contributor.authorFlierdt, J. van de
dc.contributor.authorLoumi, S.
dc.contributor.authorBonaterra, G.
dc.contributor.authorKramer, F.-J.
dc.contributor.authorFehr, M.
dc.contributor.authorTillmann, H.-C.
dc.contributor.authorForssmann, F. G.
dc.contributor.authorMaronde, E.
dc.date.accessioned2018-11-07T11:05:39Z
dc.date.available2018-11-07T11:05:39Z
dc.date.issued2007
dc.description.abstractThe circulating hormonal form Of human parathyroid hormone (hPTH-1-37) has been assessed in vitro as well as in vitro in the ovariectomized rat, a model for postmenopausal osteoporosis. In vitro, hPTH-1-37 induces a dose-depcndent cAMP formation and increases vitality as well as alkaline phosphatase activity in UMR106 ostcosarcoma cells. Differentiation and proliferation of osteoclasts in rat bone marrow-derived stem cell preparations are decreased. Daily hPTH-1-37 s.c. administration in ovariectomized rats for 60 days results in augmented formation of new bone, in amplified femural bone density, and in thickening of the calvaria.
dc.identifier.isi000244112500003
dc.identifier.pmid17363353
dc.identifier.urihttps://resolver.sub.uni-goettingen.de/purl?gro-2/52117
dc.language.isoen
dc.notes.statuszu prüfen
dc.notes.submitterNajko
dc.relation.issn0949-2321
dc.titleIntermittent administration of the circulating form of human parathyroid hormone (hPTH-1-37) prevents bone loss in ovariectornized rats
dc.typejournal_article
dc.type.internalPublicationyes
dc.type.peerReviewedyes
dspace.entity.typePublication

Files

Collections

Publications